Pulmonary Arterial Hypertension (PAH) Market Share Analysis Report, 2022-2030
The global Pulmonary Arterial Hypertension (PAH) market size was estimated at USD 6.9 billion in 2021 and is expected to surpass around USD 15.5 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 7.4% during the forecast period 2022 to 2030. Increase in initiatives by key players, higher cases of pulmonary arterial hypertension, rise in adoption rate, availability of reimbursement, and entry of generics are projected to drive the global market during the forecast period.
Increase in Collaborations for Development of Novel Products: Key Driver
Report Scope of the Pulmonary Arterial Hypertension (PAH) Market
|
Report Coverage |
Details |
|
Market Size |
USD 15.5 Billion by 2030 |
|
Growth Rate |
CAGR of 7.4% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Drug Class, Pipeline Analysis And Geography, |
|
Companies Mentioned |
|
Increase in Awareness about Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare and progressive disorder, characterized by high blood pressure in pulmonary arteries that carry blood from the heart to the lungs. PAH occurs when pulmonary arteries become narrow in diameter or get blocked. In the past few years, there has been an increasing prevalence of PAH disorder due to rising risk factors such as HIV, sedentary lifestyle, tobacco and alcohol consumption, smoking, and other idiopathic conditions. There are high-growth opportunities for market players in the near future due to increasing prevalence of PAH across the globe.
Various treatments are available in the market that helps in controlling and slowing down the growth of the diseases and improving the quality of life. In addition, the approval of few effective drugs and the occurrence of favorable pipeline are some of primary factors that drive the global market. Moreover, favorable policies by government has contributed in boosting the demand in the global pulmonary arterial hypertension market.
Rapid Growth in Geriatric Population to Fuel Market Expansion
The increase in geriatric population in developing countries is expected to drive the global pulmonary arterial hypertension market in the upcoming years. The rising incidence of PAH in the geriatric population is driving the global pulmonary arterial hypertension market during the forecast period. Aging is one of the non-modifiable factors that increases the risk related to PAH. Elderly people are more susceptible to this disease due to diastolic dysfunction and age-associated blood vessel stiffening. Several educational programs have been initiated by key market contributors and governments to increase awareness about PAH among healthcare providers and patients. All these factors are expected to boost the global pulmonary arterial hypertension market over the next few years.
Technological Advancements and Approval of New Drugs to Drive Global Market
Technological advancements in drug discovery & development, along with rising research & development activities across the globe are driving the pulmonary arterial hypertension (PAH) market. Based on drug class, the global pulmonary arterial hypertension (PAH) market has been classified into prostacyclin & prostacyclin analogs, PDE-5 inhibitors, ERAs (endothelin receptor antagonists), and soluble guanylate cyclase (sGC) stimulators. The prostacyclin & prostacyclin analogs segment is expected to dominate the market in the near future due to high demand. The SGC simulators segment is anticipated to grow at a rapid pace during the forecast period. sGC stimulators can ensure maximum activation of sGC by potentiating NO-sGC signaling. Riociguat (Adempas from Bayer) is the only drug approved for PAH in this category.
Promising Drug Pipeline to Boost Market in North America
Geographically, North America is projected to dominate the global pulmonary arterial hypertension (PAH) market during the forecast period. North America is followed by Europe, and the market in both regions is projected to grow remarkably throughout the forecast period. This can be ascribed to the availability of commercialization of new PAH drugs coupled with a promising drug pipeline. In addition, growing awareness among people in both regions about the rising availability of treatment for pulmonary arterial hypertension is also pushing the market growth.
Moreover, Asia Pacific possess lucrative opportunities for the market players. Countries such as Japan, New Zealand, Australia, China, and India are projected to offer high growth opportunities attributing to growing penetration of global players.
Side Effects Associated with PAH Drugs: Key Restraint
Some of the prominent players in the Pulmonary Arterial Hypertension (PAH) Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Pulmonary Arterial Hypertension (PAH) market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pulmonary Arterial Hypertension (PAH) Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, 2017–2030
5. Key Insights
5.1. Healthcare Industry Overview
5.2. Top 3 players operating in the market space
5.3. Technological Advancements
5.4. Key Mergers & Acquisitions
5.5. Disease Prevalence & Incidence Rate globally with key countries
5.6. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
6. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2030
6.3.1. Prostacyclin & Prostacyclin Analogs
6.3.2. Endothelin Receptor Antagonists (ERAs)
6.3.3. Phosphodiesterase-5 (PDE-5) Inhibitors
6.3.4. Soluble Guanylate Cyclase (sGC) Stimulators
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, by Pipeline Analysis
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Pipeline Analysis, 2017–2030
7.3.1. Early-stage Drug Candidates (Phase I & Phase II)
7.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
7.4. Market Attractiveness Analysis, by Pipeline Analysis
8. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Region
9. North America Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2017–2030
9.2.1. Prostacyclin & Prostacyclin Analogs
9.2.2. Endothelin Receptor Antagonists (ERAs)
9.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
9.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
9.3. Market Value Forecast, by Pipeline Analysis, 2017–2030
9.3.1. Early-stage Drug Candidates (Phase I & Phase II)
9.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
9.4. Market Value Forecast, by Country, 2017–2030
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Pipeline Analysis
9.5.3. By Country
10. Europe Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2030
10.2.1. Prostacyclin & Prostacyclin Analogs
10.2.2. Endothelin Receptor Antagonists (ERAs)
10.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
10.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
10.3. Market Value Forecast, by Pipeline Analysis, 2017–2030
10.3.1. Early-stage Drug Candidates (Phase I & Phase II)
10.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
10.4. Market Value Forecast, by Country/Sub-region, 2017–2030
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Pipeline Analysis
10.5.3. By Country/Sub-region
11. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2030
11.2.1. Prostacyclin & Prostacyclin Analogs
11.2.2. Endothelin Receptor Antagonists (ERAs)
11.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
11.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
11.3. Market Value Forecast, by Pipeline Analysis, 2017–2030
11.3.1. Early-stage Drug Candidates (Phase I & Phase II)
11.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
11.4. Market Value Forecast, by Country/Sub-region, 2017–2030
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Pipeline Analysis
11.5.3. By Country/Sub-region
12. Latin America Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2030
12.2.1. Prostacyclin & Prostacyclin Analogs
12.2.2. Endothelin Receptor Antagonists (ERAs)
12.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
12.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
12.3. Market Value Forecast, by Pipeline Analysis, 2017–2030
12.3.1. Early-stage Drug Candidates (Phase I & Phase II)
12.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
12.4. Market Value Forecast, by Country/Sub-region, 2017–2030
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Pipeline Analysis
12.5.3. By Country/Sub-region
13. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2030
13.2.1. Prostacyclin & Prostacyclin Analogs
13.2.2. Endothelin Receptor Antagonists (ERAs)
13.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
13.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
13.3. Market Value Forecast, by Pipeline Analysis, 2017–2030
13.3.1. Early-stage Drug Candidates (Phase I & Phase II)
13.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
13.4. Market Value Forecast, by Country/Sub-region, 2017–2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Pipeline Analysis
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2022
14.3. Company Profiles
14.3.1. Actelion Pharmaceuticals Ltd.
14.3.1.1. Company Overview (HQ, Business Segments, Employee)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Gilead Sciences, Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. Pfizer, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. GlaxoSmithKline plc
14.3.4.1. Company Overview (HQ, Business Segments, Employee)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. United Therapeutics Corp
14.3.5.1. Company Overview (HQ, Business Segments, Employee)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. Novartis International AG
14.3.6.1. Company Overview (HQ, Business Segments, Employee)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. Bayer HealthCare
14.3.7.1. Company Overview (HQ, Business Segments, Employee)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Other prominent players
14.3.8.1. Company Overview (HQ, Business Segments, Employee)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers